<DOC>
	<DOCNO>NCT02971319</DOCNO>
	<brief_summary>This study aim assess technical performance Tc-99m tetrofosmin SPECT compare F-18 FDG PET differentiation radiation necrosis glioma relapse obtain estimate diagnostic accuracy Tc-99m tetrofosmin SPECT F-18 FDG PET intra-individual comparison .</brief_summary>
	<brief_title>Technical Performance Assessment Tc-99m Tetrofosmin Differentiation Recurrence v Radiation Necrosis Patients With Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Technetium Tc 99m 1,2-bis ( bis ( 2-ethoxyethyl ) phosphino ) ethane</mesh_term>
	<criteria>1. confirm high grade glioma ( e.g. , anaplastic astrocytoma , glioblastoma , anaplastic oligodendroglioma , anaplastic oligoastrocytoma ) 2. followup least 3 month completion radiation therapy ( without concurrent chemotherapy ) 3. inconclusive MRI result regard differentiation recurrence radiation necrosis 4. willing able undergo study procedures 5. informed consent writing ( dated sign ) 1. age : le than18 year 2. female , pregnant breast feeding ( female childbearing potential must use adequate contraception must negative pregnancy test perform within 7 day prior inclusion study ) 3. contraindication Tc99m tetrofosmin 4. contraindication F18 FDG 5. close affiliation investigational site ; e.g . firstdegree relative investigator 6. participate another therapeutic clinical trial complete study participation another therapeutic clinical trial within 5 day enrolment trial 7. previously enrol clinical trial 8. mentally disabled 9. mental condition render subject incapable understand nature , scope , consequence trial 10 . Being clinically unstable require emergency treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>